Relation between abnormalities of heamostasis and neoangiogenesis cancer patients;Zaburzenia hemostazy a nasilenie procesu neoangiogenezy u chorych na raka piersi

Wspolczesna Onkologia

Volumn 10, Issue 10, 2006, Pages 515-520

  Łojko, Anna ^a   Zawilska, Krystyna ^a   Grodecka Gazdecka, Sylwia ^a   Komarnicki, Mieczysław ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Angiogenesis; Breast cancer; D dimer; Haemostasis; VEGF

Indexed keywords

ALPHA 2 ANTIPLASMIN; D DIMER; FIBRINOGEN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLOOD CLOTTING DISORDER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBOCYTE COUNT; TUMOR VASCULARIZATION;

EID: 33846289185     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Otten H-M, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001; 102: 187-94.
2. Wojtukiewicz M. Zakrzepy a nowotwory. W: Zakrzepy i zatory, Łopaciuk S (red.). PZWL, Warszawa 2002.
3. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
4. Piccioli A, Prandoni P Venous thromboembolism as first manifestation of cancer. Acta Haematol 2001; 106: 13-17.
5. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancer associated with venous thromboembolism. NEJM 2000; 343: 1846-50.
6. Lee AYY. Treatment of venous thromboembolism in cancer patients. Thromb Research 2001; 102: 195-208.
7. Bergqvist D. Venous thromboembolism and cancer: prevention of VTE. Thromb Res 2001; 102: 209-13.
8. Letai A, Kuter DJ. Cancer, coagulation and anticoagulation. Oncologist 1999; 4: 443-9.
9. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor Wells. Blood 2000; 96: 3302-9.
10. Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002; 30: 201-7.
11. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993; 54: 793-806.
12. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987; 57: 673-86.
13. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102: 215-24.
14. Dvorak HF. Tumors: wounds that do not heal. NEJM 1986; 315: 1650-9.
15. Wojtulkiewicz MZ, Rucińska M. Aktywacja krzepniȩcia krwi u chorych na nowotwory: implikacje kliniczne. Nowotwory 1999; 49: 381-91.
16. Brown LF, van de Water L, Harvey VS, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and tumor stroma. Am J Path 1988; 130: 455-65.
17. Bouchet C, Hacene K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048-57.
18. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Reviews 2001; 15: 61-7.
19. Kwaan HC, Parmar S, Wang J. Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost 2003; 29: 283-90.
20. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
21. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999; 77: 527-43.
22. Gawrychowski K, Skopińska-Rózewska E, Barcz E i wsp. Rola naczyniowego czynnika wzrostu śródbłonka (VEGF) w powstawaniu wysiȩku otrzewnowego u chorych na raka jajnika. Nowotwory 1999; 49: 19-20.
23. Nagy JA, Masse EM, Herberg KT, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res 1995; 55: 360-8.
24. Ribatti D, Vacca A, De Falco G, Ria R, Roncali L, Dammacco F. Role of hematopoietic growth factors in angiogenesis. Acta Haematol 2001; 106: 157-61.
25. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108: 2368-79.
26. Bertolini F, Mancuso P, Gobbi A, Pruneri G. The thin red line: angiogenesis in normal and malignant hematopoesis. Exp Hematol 2000; 28: 993-1000.
27. Ferrara N. VEGF and the quest for turmour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803.
28. Gerber HP, Ferrara N. The role of VEGF In normal and neoplastic hematopoiesis. J Mol Med 2003; 81; 20-31.
29. Risau W. Mechanism of angiogenesis. Nature 1997; 186: 671-4.
30. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
31. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999; 5: 1041-56.
32. De Vita F, Orditura M, Lieto E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004; 100: 270-8.
33. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87: 1237-45.
34. Thielemann A, Kopczyński Z, Grodecka-Gazdecka S, Piekarska B. Ocena stȩżenia naczyniowo-śródbłonkowego czynnika wzrostu VEGF u chorych na raka gruczołu piersiowego. Diag Lab 2005; 41: 154-61.
35. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectonny. J Clin Oncol 2004; 22: 1655-63.
36. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR correlates with vascularity, metastasis and proliferation of human colon cancer. Can Res 1995; 55: 3964-68.
37. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002; 95: 1923-30.
38. Chan LW, Moses MA, Coley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 2004; 22: 499-506.
39. Lind SE, Caprini JA, Goldshteyn S, Dohnal JC, Vesely SK, Shevrin DH. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost 2003; 89: 185-9.
40. Roselli M, Mineo TC, Basili S, et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 2003; 89: 177-84.
41. Seo, Y, Baba H, Fakuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and poor prognosis in ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-45.
42. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103: 955-62.
43. Lee JH, Ryu KW, Kim S, Bae JM. Preoperative plasma fibrinogen levels in gastric cancer correlate with extent of tumor. Hepatogastroenterol 2004; 51: 1860-3.
44. Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study Thromb Haemost 2001; 86: 828-33.
45. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 1979; 71: 10-16.
46. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600-8.
47. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101: 77-82.
48. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-95.
49. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996; 60: 197-202.
50. Kim HK, Song KS, Lee KR, Kang YH, Lee YJ, Lee ES. Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis 2004; 15: 9-13.
51. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today 1998; 28: 373-8.
52. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997; 52: 563-565
53. Wojtukiewicz MZ, Rucinska M, Kloczko J, Dib A, Galar M. Profiles of plasma serpins in patients with advanced malignant melanoma, gastric cancer and breast cancer. Haemostasis 1998; 28: 7-13.
54. Negrier S, Perol D, Menetrier-Caux C, et al.; Groupe Francais d'Immunotherapie. Interleukin-6, interieukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotheraple. J Clin Oncol 2004; 22: 2371-8.
55. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoaguiation on survival in carcinoma of the lung, colon, head and neck and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53: 2046-52.
56. Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparyn therapy in cancer patients. The Oncologist 2005; 10: 72-9.
57. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
58. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
59. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inclucible factor-1 and the down-regulation of VEGF gene expression. Cancer 2004; 100: 201-10.